Myriad Genetics (MYGN) Equity Ratio (2010 - 2026)

Myriad Genetics has disclosed Equity Ratio across 17 years of filings, most recently posting 0.5 for Q1 2026.

• In Q1 2026, Equity Ratio fell 28.52% year-over-year to 0.5; the TTM figure through Mar 2026 stood at 0.5 (down 28.52% YoY), while the FY2025 annual figure was 0.52, down 23.67% from the prior year.
• Equity Ratio fell to 0.5 in Q1 2026, from 0.52 in the prior quarter.
• Over the last five years, Equity Ratio for MYGN reached as high as 0.78 in Q2 2022 and fell as low as 0.5 in Q1 2026.
• The 5-year median for Equity Ratio is 0.68 (2024), against an average of 0.66.
• Annual changes were most pronounced in 2022 — Equity Ratio increased 18.01% — and 2026, when it slipped 28.52%.
• A 5-year view of Equity Ratio shows it stood at 0.74 in 2022, then dropped by 7.56% to 0.68 in 2023, then dropped by 0.12% to 0.68 in 2024, then dropped by 23.67% to 0.52 in 2025, then slipped by 3.84% to 0.5 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.5, 0.52, and 0.51 for Q1 2026, Q4 2025, and Q3 2025 respectively.